Join us for Curebound Night at the Ballpark June 21. $10 from every ticket purchase goes back to Curebound. Tickets here.

Advancing Immune Checkpoint Inhibition of PSGL-1 for Treatment of Malignant Melanoma

Skin Cancer

Curebound

Novel Approaches and New Therapeutic Platforms

Immunotherapies and Personalized Vaccines

Linda Bradley (SBP)

Soo Jin Park (UCSD)

Despite recent advances, malignant melanoma still causes thousands of deaths in the US each year. The goal of this project is to develop a novel, monoclonal antibody-based therapy that can reactivate the tumor-killing properties of the patient’s own immune system. This therapy has the potential to eradicate tumors that are refractory to existing therapy and thus save lives.

Curebound

EXPLORATION

Curebound
Curebound

ACCELERATION

Curebound
Curebound

COLLABORATION

Curebound
Curebound

CURES